{"contentid": 488070, "importid": NaN, "name": "NICE nods through Daiichi Sankyo\u00e2\u0080\u0099s cholesterol drugs", "introduction": "The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending the provision of Nilemdo (bempedoic acid) and Nustendi (bempedoic acid/ ezetimibe) on the National Health Service (NHS) in England.", "content": "<p>The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending the provision of Nilemdo (bempedoic acid) and Nustendi (bempedoic acid/ ezetimibe) on the National Health Service (NHS) in England.</p>\n<p>Daiichi Sankyo&rsquo;s (TYO: 4568) two drugs have been recommended for treating primary hypercholesterolemia or mixed dyslipidemia (heterozygous familial and non-familial) as an adjunct to diet, only if statins are contraindicated or not tolerated, and ezetimibe alone does not control low-density lipoprotein cholesterol (LDL-C) well enough.</p>\n<p><span class=\"pullQuote\">\"Availability of treatments such as these is essential in tackling cardiovascular disease\"</span>This recommendation is an important milestone for patients who will have access to two important new treatment options for lowering LDL-C, a leading risk factor for cardiovascular events, such as heart attack or stroke.</p>\n<p>Cardiovascular disease is one of the main causes of death and disability in the UK, with more than&nbsp;seven million people affected, and it is estimated that close to half of the adult population are living with cholesterol levels above national guidelines.</p>\n<p>England is the first country in Europe to be granted access.</p>\n<p>Kausik Ray, professor of public health and honorary consultant cardiologist, Imperial College London, said: &ldquo;Until now, patients with hypercholesterolemia who cannot tolerate statins have had limited treatment options to effectively reduce their LDL-C levels, which is a leading modifiable risk factor of cardiovascular disease.</p>\n<p>&ldquo;Today&rsquo;s announcement is fantastic news for patients as it marks the first new oral treatment options for high cholesterol to be made available in over a decade. Availability of treatments such as these is essential in tackling cardiovascular disease, the leading cause of death in the UK. When it comes to heart health and cholesterol, there is no such thing as &lsquo;too low LDL-C&rsquo;, highlighting the importance of treatments for high-risk patients.&rdquo;</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>", "date": "2021-03-18 00:01:00", "meta_title": NaN, "meta_keywords": "Daiichi Sankyo, United Kingdom, health, national, cholesterol, cardiovascular, ezetimibe, disease, nods, Institute, Care, Excellence, primary, mixed, NICE", "meta_description": "The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending the provision of Nilembo (bempedoic acid) ", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "2021-03-18 00:01:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-17 17:00:55", "updated": "2021-03-18 10:20:56", "access": NaN, "url": "https://www.thepharmaletter.com/article/nice-nods-through-daiichi-sankyo-s-cholesterol-drugs", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "daiichi-hq.jpg", "image2id": "daiichi-hq-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Cardio-vascular", "topic_tag": "Focus On, Pricing, reimbursement and access", "geography_tag": "Japan, UK", "company_tag": "Daiichi Sankyo", "drug_tag": "Nilembo, Nustendi", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-18 00:01:00"}